A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer

Summary

This is a phase Ib/II clinical study. All participants are patients with advanced colorectal cancer (CRC). The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary anti-tumor efficacy of HDM2017 in combination with standard of care in patients with advanced CRC.

Timeline

Start

2026-07-15

Primary completion

2027-11-01

Completion

2028-11-01

Drugs

Indications